drugset / Trial / NCT05889442
Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab
RandomizedCrossoverQuadruple-blindOther
Summary
An outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. Here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody).
Timeline
- Start
- 2023-03-09
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levcromakalim | Small molecule | 0.05 mg | Intravenous |